Summary by Moomoo AI
Cormorant Asset Management, LP, and Bihua Chen have filed an amended Schedule 13G/A with the SEC, indicating a shared voting and dispositive power over 8,325,000 shares of EyePoint Pharmaceuticals, Inc. This represents 12.20% of the company's class of common stock. The filing, dated September 30, 2024, and disclosed on November 14, 2024, suggests that the shares are held in the ordinary course of business and not with the intent to change or influence the control of the issuer. The shares are directly held by the Cormorant Funds, with Cormorant Global Healthcare Master Fund, LP having the right to receive dividends or proceeds from the sale of more than 5% of the shares. The filing is a routine disclosure by investment advisers and control persons regarding their holdings and is not an admission of beneficial ownership of the reported shares.